Ofloxacin 0.75% + Ornidazole 2.0% + Itraconazole 1% + Clobetasol 0.05%
| Composition | Ofloxacin 0.75% + Ornidazole 2.0% + Itraconazole 1% + Clobetasol 0.05% |
|---|---|
| Packing | 15 gm |
| MRP | ₹ 74 |
| Dosage Form | Topical |
Oflozia Cream is a broad-spectrum topical combination cream containing Ofloxacin 0.75%, Ornidazole 2.0%, Itraconazole 1%, and Clobetasol 0.05%. This four-in-one formulation is designed to tackle complex skin infections that involve a combination of bacterial, fungal, and anaerobic organisms — all while controlling inflammation and itching.
This type of combination cream is commonly prescribed for mixed skin infections where multiple organisms may be present simultaneously, providing a comprehensive treatment approach in a single application.
This medicine is commonly used for:
Indicated for topical treatment of mixed dermatological infections involving susceptible Gram-positive and Gram-negative bacteria (Ofloxacin), anaerobic organisms (Ornidazole), dermatophytes and Candida species (Itraconazole), along with concurrent inflammatory symptoms managed by Clobetasol propionate. Appropriate for conditions such as infected eczema, infected intertrigo, and tinea with secondary bacterial infection.
Ofloxacin targets bacteria on the skin, while Ornidazole works against anaerobic microbes that thrive in low-oxygen environments. Itraconazole kills fungal organisms responsible for ringworm and similar infections. Clobetasol reduces the redness, swelling, and itching that come with skin inflammation, helping the skin feel more comfortable as the infection clears.
Ofloxacin, a fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication. Ornidazole is a nitroimidazole that undergoes intracellular reduction to form reactive intermediates that disrupt anaerobic microbial DNA. Itraconazole inhibits fungal cytochrome P450-dependent lanosterol 14-alpha-demethylase, depleting ergosterol in fungal cell membranes and causing membrane disruption. Clobetasol propionate, a potent synthetic glucocorticoid, binds glucocorticoid receptors and suppresses NF-kB-mediated transcription of pro-inflammatory cytokines, reducing the inflammatory response.
Mixed skin infections — where fungi, bacteria, and anaerobic organisms are all present — are particularly common in warm, humid climates like India, especially in skin folds and between toes. Combination creams like Oflozia are designed to address this clinical reality in a single step.
Apply Oflozia Cream to the affected area as directed by your dermatologist, typically once or twice daily. Always follow the prescribed duration — do not use for longer than advised, especially given the corticosteroid content. Wash and dry the area before applying.
Always follow the dosage and schedule advised by your doctor — this is general guidance only.
Mild burning, stinging, or itching at the site of application may occur initially. Prolonged use of clobetasol-containing preparations can cause skin thinning, stretch marks, or increased susceptibility to infection if used beyond the recommended period. Tell your doctor if any side effect is severe or persistent.
If a skin infection has both fungal and bacterial causes, two separate creams must always be used.
Combination topical formulations like Oflozia Cream are specifically designed to treat mixed infections in a single application, simplifying treatment and improving adherence.
Stronger steroid creams always give faster and better results for skin infections.
Corticosteroids like Clobetasol control inflammation but do not kill the infecting organism. They must always be used alongside the appropriate antimicrobial agents and for no longer than prescribed to avoid side effects such as skin thinning.
KETOCONAZOLE 20 MG + IODOCHLORHYDROXYQUINOLINE 10 MG + TOLNAFTATE 10 MG + NEOMYCIN 1 MG + CLOBETASOL PROPIONATE 0.05 MG + DEXPANTHENOL 0.5 MG
Luliconazole Cream 1.0% w/w
Diclofenac Diethylamine 1.16% Eq. to Diclofenac Sodium 1% + Methyl Salicylate 10% + Oleum Lini 3% + Menthol 5% + Benzyl Alcohol 1% w/v
HYDROQUINONE 2% + TRETINOIN 0.025% + MOMETASONE FUROATE 0.1%